[{"orgOrder":0,"company":"Medical Corps, Israel Defense Force","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Meclizine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Medical Corps, Israel Defense Force","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Corps, Israel Defense Force \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medical Corps, Israel Defense Force \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Meclizine HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medical Corps, Israel Defense Force

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Medical Corps, Israel Defense Force

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Meclizine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Motion Sickness.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 23, 2020

                          Lead Product(s) : Meclizine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Apsen Farmaceutica

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Apsen Farmaceutica

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Meclizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vertigo.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 14, 2014

                          Lead Product(s) : Meclizine Hydrochloride

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Duke University

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Duke University

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Meclizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Smoking Cessation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 30, 2011

                          Lead Product(s) : Meclizine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Philip Morris USA, Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank